PRAXIS PRECISION MEDICINES INC

NASDAQ: PRAX (Praxis Precision Medicines, Inc)

Last update: 7 hours ago

316.14

-4.10 (-1.28%)

Previous Close 320.24
Open 325.12
Volume 252,273
Avg. Volume (3M) 460,851
Market Cap 8,804,762,624
Price / Sales 953.14
Price / Book 9.84
52 Weeks Range
28.79 (-90%) — 356.00 (12%)
Earnings Date 30 Apr 2026
Operating Margin (TTM) -2,868.84%
Diluted EPS (TTM) -10.66
Quarterly Revenue Growth (YOY) 1,349.10%
Total Debt/Equity (MRQ) 0.24%
Current Ratio (MRQ) 8.44
Operating Cash Flow (TTM) -163.91 M
Levered Free Cash Flow (TTM) -90.04 M
Return on Assets (TTM) -39.95%
Return on Equity (TTM) -63.56%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock Praxis Precision Medicines, Inc Bullish Bullish

AIStockmoo Score

-0.3
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -4.5
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average -0.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
PRAX 9 B - - 9.84
AXSM 9 B - - 97.63
IBRX 8 B - - -
XENE 6 B - - 9.33
TGTX 5 B - 12.18 8.27
TARS 3 B - - 8.99

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 0.16%
% Held by Institutions 122.02%

Ownership

Name Date Shares Held
Baker Bros. Advisors Lp 31 Dec 2025 1,126,488
Cormorant Asset Management, Lp 31 Dec 2025 950,000
Driehaus Capital Management Llc 31 Dec 2025 933,061
Deerfield Management Company, L.P. 31 Dec 2025 903,351
52 Weeks Range
28.79 (-90%) — 356.00 (12%)
Price Target Range
130.00 (-58%) — 1,245.00 (-99%)
High 1,245.00 (HC Wainwright & Co., 293.81%) Buy
Median 510.00 (61.32%)
Low 130.00 (Wedbush, -58.88%) Sell
Average 647.00 (104.66%)
Total 7 Buy, 1 Hold, 1 Sell
Avg. Price @ Call 325.73
Firm Date Target Price Call Price @ Call
Wolfe Research 24 Feb 2026 500.00 (58.16%) Buy 342.71
Baird 20 Feb 2026 433.00 (36.96%) Buy 335.28
Truist Securities 20 Feb 2026 700.00 (121.42%) Buy 335.28
Wedbush 20 Feb 2026 130.00 (-58.88%) Sell 335.28
12 Jan 2026 95.00 (-69.95%) Sell 275.74
Wells Fargo 20 Feb 2026 305.00 (-3.52%) Hold 335.28
02 Feb 2026 282.00 (-10.80%) Hold 309.11
Guggenheim 10 Feb 2026 800.00 (153.05%) Buy 320.48
Needham 04 Feb 2026 510.00 (61.32%) Buy 303.34
HC Wainwright & Co. 30 Jan 2026 1,245.00 (293.81%) Buy 314.00
Piper Sandler 28 Jan 2026 1,200.00 (279.58%) Buy 309.92
Show more

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria